№ lp_2_3_26886
File format: docx Character count: 10721 File size: 64 KB
A standardized template for reporting HER2 biomarker testing results in patients with adenocarcinoma of the stomach or gastroesophageal junction.
Version: GastricHER2Biomarkers 1.0.0.1
Protocol Posting Date: June 2017
Year: 2017
Region / city: United States
Topic: HER2 biomarker testing, gastric cancer, gastroesophageal junction
Document type: Guideline
Organization / institution: College of American Pathologists, American Society for Clinical Pathology, American Society of Clinical Oncology
Author: Angela N. Bartley, MD; Jessi Christ, CTR; Patrick Fitzgibbons, MD; Stanley R. Hamilton, MD; Sanjay Kakar, MD; Manish A. Shah, MD; Laura H. Tang, MD, PhD; Megan L. Troxell MD, PhD
Target audience: Pathologists, oncologists, clinical laboratories
Period of validity: Indefinite
Date of approval: June 2017
Date of changes: N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Expression and chromatin accessibility analysis of HER2 in SKBR3 and SKBR3-L cells
Year: 2026
Region / city: Not specified
Subject: Molecular biology, cell signaling
Document type: Supplementary figure description
Institution: Not specified
Author: Not specified
Cell lines: SKBR3, SKBR3-L
Experimental techniques: Fluorescence microscopy, imageJ analysis, chromatin accessibility assay, MA plot analysis
Statistical analysis: Unpaired t-test with Welch’s correction, p < 0.0001, adjusted p < 0.05
Magnification: 20x
Scale bars: 50 μm
Data points: n = 79 for parental cells, n = 31 for lapatinib-resistant cells
Target protein: HER2
Genomic features: Transcription start sites (TSS), nucleosome positioning
Comprehensive molecular classification for adenocarcinoma of gastroesophageal junction between esophageal and gastric adenocarcinomas
Year: 2016
Region / city: Seoul, Korea
Subject: Medical research, Oncology
Document type: Supplementary Methods
Organization / institution: Seoul National University, Jackson Laboratory for Genomic Medicine, MD Anderson Cancer Center
Authors: Yun-Suhk Suh, Deukchae Na, Ju-Seog Lee, Jeesoo Chae, EuiHyun Kim, Giyong Jang, Jieun Lee, Jimin Min, Chan-Young Ock, Seong-Ho Kong, Joshy George, Chengsheng Zhang, Hyuk-Joon Lee, Jong-Il Kim, Seong-Jin Kim, Woo Ho Kim, Charles Lee, Han-Kwang Yang
Target audience: Researchers, medical professionals, academicians
Date of approval: 2016
Date of modifications: None
EGFR gene copy number in 44 gastroesophageal adenocarcinomas from the IRCC dataset with copy number gain
Year: 2026
Dataset: IRCC gastroesophageal adenocarcinomas
Gene: EGFR
Number of tumors analyzed: 44
Type of data: Supplementary table
Method: qReal Time PCR
Sample type: Patient tumors and corresponding PDX when available
Notes: Tumors with heterogeneous copy number gain marked with a star
ILUSTRO: Phase 2 Multicohort Trial of Zolbetuximab in Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Year: 2023
Study Type: Clinical trial, Phase 2
Document Type: Supplementary data
Authors: Samuel J. Klempner et al.
Intervention: Zolbetuximab monotherapy, Zolbetuximab + mFOLFOX6, Zolbetuximab + Pembrolizumab
Population: Patients with advanced or metastatic claudin 18.2–positive gastric or gastroesophageal junction adenocarcinoma
Sample Size: 54
Countries: France, Italy, Japan, Korea, Taiwan, United States
Cohorts: 1A, 2, 3A
Age Range: 32–79 years
Median Age: 60–65 years
Sex Distribution: Male 33, Female 21
Ethnicity: Asian 43%, White 43%, Black 2%, Hispanic/Latino 6%
PK Sampling: Zolbetuximab, mFOLFOX, Pembrolizumab
HRQOL Assessment: Multiple cycles per cohort
Follow-up: 30-day safety, 90-day follow-up
Geographic Focus: Eastern Asia, Central/Eastern Europe, United States, France
End Points: Pharmacokinetics, health-related quality of life, patient demographics
Data Sources: Clinical study data, GLOBOCAN 2020, literature references
Supplementary Materials: Methods, Tables, Figures
Ultrasound Examination for Gastroesophageal Reflux in Children
Year: 2026
Region / City: Kainuu, Finland
Document Type: Medical appointment instructions
Institution: Kainuu Central Hospital
Target Audience: Pediatric patients and their guardians
Preparation Requirements: Fasting 2 hours before examination, bring drink in bottle or breast-feed
Examination Duration: 10 minutes
Examination Focus: Lower esophagus and upper stomach to monitor reflux
Post-Examination Instructions: No special treatment required, results communicated by attending physician
Contact Information: Telephone provided for rescheduling or inquiries
Fees: Possible charge for missed or non-cancelled appointments
Topics: ERBB2 HER2 Gastroesophageal